Herein, we showed that BMI1 inhibitors could efficiently block GBM neural sphere growth and CSC viability in four independent patient-derived GBM cell lines, suggesting that drug-mediated BMI1 inhibition is a versatile treatment for most patients with GBM. Here, BMI1 is linked to glioblastoma.